Safe Money Report Bomb in the Basement Review 2026: Legit or Hype?
A compliance-focused overview examines the $49 Safe Money Report offer, publisher's-exclusion positioning, performance-risk disclosures, bonus guide details, refund terms, and key verification steps for readers evaluating the campaign heading into 2026.
NEW YORK CITY, NEW YORK / ACCESS Newswire / February 19, 2026 / Disclaimers: This article is for informational purposes only and does not constitute professional financial or investment advice. Results vary based on individual use, timing, market conditions, and circumstances. Investing involves risk, including potential loss of principal. This article contains affiliate links. If you click on these links and make a purchase, a commission may be earned at no additional cost to you. This compensation does not influence the information presented.
Safe Money Report Bomb in the Basement: What Weiss Ratings' 2026 "Health Bomb" Presentation Claims and What Subscribers Should Verify
If you have been scrolling through Facebook, YouTube, or Instagram lately, chances are good you have seen the ad. Dr. Martin Weiss, founder of Weiss Ratings, standing in front of charts warning about a healthcare-driven economic collapse he compares to 2008. The presentation is called the "Health Bomb," and according to the company, the pressure becomes most visible toward the end of the year, often framed around the fourth quarter and the following year's premium notices.
The pitch ends with an offer to join Safe Money Report for $49 per year, which includes six bonus Crisis Profit Guides, 18 specific investment recommendations, and access to the company's financial instrument ratings database.
You are here because you did what any smart person does before spending money based on an online ad. You Googled it. Good. That is exactly what you should do, and this review is built to give you everything you need to make an informed decision.
See the current Safe Money Report offer
Disclosure: If you buy through this link, a commission may be earned at no extra cost to you.
Always confirm the exact bonuses, renewal terms, and total price shown on the final order form before purchase.
Let us walk through what Safe Money Report actually is, who is behind it, what the healthcare thesis claims, what you get for your $49, and whether it is worth your time and money heading into 2026.
What Is Safe Money Report?
Safe Money Report is a monthly investment research newsletter published by Weiss Ratings, LLC. According to the company, it has been in publication for decades and serves as the flagship outlet for Weiss Ratings' macro market commentary, stock recommendations, and crisis-oriented investing strategies.
According to the company's published terms, Weiss Ratings, LLC is "strictly a financial research publishing firm (a publisher) and does not provide individual investment advice." Weiss Ratings is not a registered investment adviser or broker/dealer. The service operates under what is known as the publisher's exclusion from investment adviser registration. The newsletter is currently edited by Nilus Mattive, with Dr. Weiss serving as Editor Emeritus. This means the stock ratings and commentary represent the publisher's opinions and methodology, not personalized recommendations tailored to any individual subscriber's financial situation.
What this means for you practically is that every subscriber receives the same information regardless of their personal portfolio, risk tolerance, or financial goals. The research is general in nature, and the company explicitly states that their information "is not intended to be used as customized recommendations to buy, hold or sell securities."
This is an important distinction. Safe Money Report is a research tool and educational resource, not a financial advisor replacement. How you use the information is entirely your responsibility.
Who Is Dr. Martin Weiss and Weiss Ratings?
Understanding who is behind the product matters when evaluating any financial publication.
Dr. Martin D. Weiss is the founder and president of Weiss Ratings, LLC, headquartered in Palm Beach Gardens, Florida. According to the company's published materials, Dr. Weiss holds a doctoral degree from Columbia University and has been involved in financial research and publishing for over 30 years.
The company claims several notable accomplishments in their published materials. According to their own reporting, Dr. Weiss is on record predicting the Savings and Loan Crisis, the dot-com bust, and the 2008 Global Financial Crisis. Weiss also cites a U.S. Government Accountability Office (GAO) report that, according to Weiss, found its insurer ratings outperformed major agencies in warning of future insurer financial trouble. Additionally, according to the company, a study reported in the Wall Street Journal found that investors using Weiss stock ratings could have outperformed Goldman Sachs, Merrill Lynch, Morgan Stanley, JP Morgan Chase, and 18 other firms.
These are the company's own claims drawn from their published marketing materials. The GAO study and the Wall Street Journal study are cited as public record, and interested readers can research these references independently to evaluate them.
The company currently publishes ratings and analysis across a broad range of financial instruments. The presentation materials reference "over 65,000" stocks, ETFs, mutual funds, digital assets, banks, credit unions, and insurance companies, while the subscription offer page describes access to 53,000 Weiss ratings (valued separately at $228 per year). This breadth of coverage is one of the distinguishing features the company emphasizes versus competitors who may focus on a narrower range of instruments.
The Healthcare "Bomb" Thesis: What Weiss Ratings Is Claiming
The current Safe Money Report marketing campaign centers on what Dr. Weiss calls the "Bomb in the Basement," a healthcare-driven economic crisis thesis. This is the company's investment thesis, and it is important to evaluate it as such rather than as established fact.
According to Weiss Ratings' analysis, five "detonators" could combine to create as much as $112 trillion in negative future economic impact to the United States. The company breaks this down as follows in their published presentation:
According to the company's thesis, the five factors are: tech-related job losses from AI and automation (which the company estimates could reach up to $66 trillion in long-term impact), dementia and declining birth rates (estimated at over $41 trillion), youth mental health and healthcare costs (estimated at $4.8 trillion), tariffs and trade wars affecting pharmaceutical imports (estimated between $500 billion and $2 trillion or more), and healthcare costs for undocumented immigrants (estimated at up to $200 billion).
The presentation argues the breaking point comes in the fourth quarter when health insurance premium notices arrive for the following year. Specifically, Dr. Weiss points to premium increases for 2027 as the potential catalyst, drawing a parallel to the 2008 adjustable-rate mortgage crisis and suggesting that consumers may similarly reach a breaking point as premiums escalate.
A few important things to keep in mind about this thesis. The $112 trillion figure represents Weiss Ratings' own projection of combined future impact across multiple decades, not an immediate or near-term dollar figure. The individual projections within this analysis involve significant assumptions about AI job displacement rates, birth rate trends, healthcare cost trajectories, and other variables that are inherently uncertain. Credible economists hold a wide range of views on these topics, and many of the long-term projections cited by the company represent worst-case scenarios within their own analysis.
None of this means the thesis is wrong. Healthcare costs, AI disruption, and demographic shifts are real concerns that many economists and policymakers are grappling with. But as with any investment thesis, it is one perspective among many, and it should be weighed accordingly.
What Do You Actually Get for $49?
According to the company's "Health Bomb" presentation, the $49 annual subscription includes what they call a 12-piece "Financial Bomb Shelter" bundle. Here is what the company states is included in this particular offer. Note that bonus reports and bundle contents can vary by promotion and landing page, so always confirm the exact bundle shown on the order form before completing your purchase.
Six Bonus Crisis Profit Guides (which the company values at $79 each, or $474 combined):
Guide 1: Three Health-Tech Stocks to Buy Now for the Age of AI Medicine. According to the company, this guide contains three specific AI healthcare stock picks, which they describe using code names including "The Pain Sniper" (described as a U.S. pharma company focused on autoimmune disorders, cancers, and AI-driven drug development), "The Swiss Army Biotech" (described as a multinational firm with 44 clinical programs and 36 approved medications), and "The Cross-Species Crusher" (described as a company with therapeutics for both humans and animals with a proprietary AI platform).
Guide 2: Two "AI Metal" Plays for a New Technology and Healthcare Age. This guide covers one silver and one copper stock pick, which the company describes as positioned to benefit from increasing industrial demand driven by AI infrastructure, data centers, and medical technology.
Guide 3: The ONLY Insurance Stock You Should Invest in Today. According to the company, this guide features a "boutique insurer" that profits partly by insuring other insurance companies and specializing in niche coverage areas like cybersecurity risk.
Guide 4: Three Big Healthcare Stocks to Avoid Like the Plague. The company describes this as a guide to three commonly held healthcare stocks they believe will underperform as the healthcare crisis unfolds.
Guide 5: The Ultimate Gold Warchest. According to the company, this guide includes nine specifically named precious metal investments along with guidance on buying physical gold, vetting dealers, and tax considerations.
Guide 6: How to Turn Market Mayhem into Cold, Hard Cash. The company describes this as a guide to a covered call income strategy that they claim has an average win rate of 82 percent using their methodology, with the potential to generate up to $1,000 per week in income. These are the company's marketing claims about their methodology. Options strategies involve risk, results vary significantly, and losses are possible. The win rate and income figures cited are not guaranteed.
Six Ongoing Core Benefits:
Monthly Safe Money Report newsletter issues with macro market commentary. A real-time Position Tracker (the company states that as of the current offer, 80 percent of their 35 open positions are in the win column, with top gains of 301 percent, 291 percent, and 227 percent). An archive of over 20 special reports and asset ranking lists. A member Q&A portal. Access to the company's financial ratings database (the presentation references over 65,000 instruments; the offer page describes 53,000 ratings). And 24/7 online member access to all resources.
Additional perks per the current offer: a free subscription to Weiss Ratings Daily (their daily financial e-letter) and a 365-day money-back guarantee.
Check current pricing and availability
About Those Performance Claims
The company's marketing materials cite "305% average returns" on all stock recommendations since 2001, and their current Position Tracker shows top open gains of 301 percent, 291 percent, and 227 percent.
Per the company's own required risk disclosure (which appears in their published terms and conditions), these are hypothetical performance results with "many inherent limitations." The company's own disclaimer states: hypothetical performance results are "generally prepared with the benefit of hindsight" and "there are frequently sharp differences between hypothetical performance results and the actual results subsequently achieved by any particular trading program."
The company's disclaimer further acknowledges that "hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk in actual trading." The featured gains cited in marketing materials represent selected highlights, not the experience of any particular subscriber. Individual investor results vary significantly based on entry timing, position sizing, holding period, portfolio allocation, and broader market conditions. Losses are possible and have occurred.
Past performance does not guarantee future results. This applies universally to all investment research services, and Safe Money Report is no exception.
Pricing, Refund Policy, and What to Verify Before Subscribing
Pricing: According to the company's current offer, Safe Money Report is available for $49 per year. The company states the regular price is $129 per year. The company calculates the total value of the bundle at $831, which includes the retail prices of the six Crisis Profit Guides ($474 at $79 each), the ratings access fee ($228 for access to 53,000 ratings), and the newsletter subscription ($129). Verify current pricing on the order page before subscribing, as promotional terms are subject to change.
Refund Policy: According to the company's published terms and conditions, Safe Money Report falls under their "Investment Research Services" category (periodicals priced under $200 per year). Per those terms, "the first-year subscription fee is fully refundable if canceled any time in the first year." After the first year, the subscription is set to renew automatically at the lowest regular renewal rate available, unless you opt out. Subscribers may cancel for a prorated refund on the balance of the current term, per the company's terms.
Important detail from the terms: The company notes that all six Crisis Profit Guides are yours to keep even if you cancel for a full refund. Contact for cancellation is available by email at [email protected] or by phone at 877-934-7778, according to the company's published terms.
Auto-renewal awareness: The subscription auto-renews after the first year. If you subscribe, note the renewal date and set a reminder to evaluate whether you want to continue before the next billing cycle.
Who Safe Money Report May Be Right For
Safe Money Report May Align Well With People Who:
Want a research starting point, not a financial advisor. If you are a self-directed investor looking for macro market commentary, specific stock ideas to research further, and access to a broad ratings database, the $49 price point represents a low entry barrier for a year of research access.
Are concerned about healthcare sector disruption and want a framework for thinking about it. Whether or not you agree with every element of the company's $112 trillion thesis, the underlying concerns about AI-driven job displacement, rising healthcare costs, and demographic shifts are topics worth having a research-based perspective on as you make investment decisions heading into 2026.
Prefer a defensive investing orientation. The "Safe Money" brand positioning suggests a focus on capital preservation alongside growth. If your investing philosophy leans toward protecting what you have while selectively pursuing upside opportunities, the editorial approach may align with your temperament.
Appreciate having a single platform with broad coverage. The combination of stock ratings, precious metals guidance, income strategies, and macro commentary in one subscription could consolidate research needs for investors who currently piece together insights from multiple free sources.
Other Options May Be Preferable For People Who:
Need personalized investment advice. Safe Money Report explicitly does not provide individualized recommendations. If you need guidance tailored to your specific financial situation, tax circumstances, and retirement timeline, a registered investment adviser or certified financial planner is more appropriate.
Are uncomfortable with promotional-style marketing. The sales presentation uses urgent, fear-driven language that is common in financial newsletter marketing. If the marketing style concerns you, understand that the editorial content of the newsletter itself may differ in tone from the advertising that promotes it.
Expect guaranteed returns or risk-free investing. No investment research service can guarantee results. The performance figures cited are hypothetical, past results, and the company's own disclaimers make clear that losses are possible.
Questions to Ask Yourself
Before subscribing to any financial newsletter, consider these questions. Do you have a clear understanding of your own investment goals and risk tolerance? Will you use the research as one input among several, rather than following recommendations without your own due diligence? Are you comfortable with the auto-renewal structure, and will you actively evaluate the service before the next billing cycle? Can you afford to lose the $49 subscription fee if you find the service is not for you, even though the refund policy provides a safety net?
Your answers help determine whether Safe Money Report, or any financial research subscription, is a productive addition to your investing toolkit.
Get started with Safe Money Report
How Safe Money Report Compares to Alternatives
The financial newsletter space is crowded, and prospective subscribers often want to know how Safe Money Report stacks up against other options. Here is some general context to help frame your evaluation.
At $49 per year, Safe Money Report sits at the lower end of the pricing spectrum for investment research subscriptions. Services like The Motley Fool's Stock Advisor and Stansberry Research publications typically carry higher annual price points. On the other end, free sources like Seeking Alpha's basic tier and Yahoo Finance provide research without a subscription fee, though generally with less specific actionable guidance.
What differentiates Safe Money Report's value proposition, according to the company, is the combination of its broad ratings database coverage (spanning stocks, funds, insurance companies, and banks), the crisis-oriented editorial perspective, and the inclusion of multiple bonus guides with specific recommendations. The company's emphasis on rating insurance companies and financial institutions is a niche that many competing services do not cover.
However, every financial research service has its own methodology, track record, and editorial perspective. The most productive approach for any investor is typically to evaluate multiple sources rather than relying on any single subscription for all investing decisions.
Final Verdict: The Case for Safe Money Report and Considerations to Weigh
The case for subscribing: At $49 for a full year, the subscription cost is low relative to most financial research services, and the company's 365-day money-back guarantee (per their published terms) means you can evaluate the service for a full year before the refund window closes. You get access to a broad ratings database, six guides with 18 specific investment recommendations, an income strategy guide, monthly macro commentary, and real-time position tracking. Of course, the subscription cost and any investment outcomes are separate considerations entirely. Investing always involves risk, including potential loss of principal, regardless of which research tools you use.
Considerations to weigh: The marketing presentation uses fear-driven urgency that is standard in financial newsletter advertising but can feel aggressive. The healthcare "bomb" thesis is the company's projection and involves significant long-term assumptions. Performance claims are hypothetical and reflect selected highlights, not guaranteed or typical subscriber outcomes. And like all financial research, the value you extract depends entirely on how you apply it alongside your own due diligence.
Important Note: The financial newsletter and investment research industry has been under ongoing regulatory scrutiny in recent years. Readers should review the most current information about any service's compliance and regulatory standing before subscribing. The SEC and FINRA both maintain public resources for evaluating financial research providers.
At the end of the day, $49 for a year of research access with a full refund guarantee is a straightforward way to evaluate whether Weiss Ratings' approach to the markets aligns with how you think about investing. The key is to use it as one tool in your toolkit, not as a replacement for your own judgment or professional financial advice.
Check the latest Safe Money Report offer
Contact Information
According to the company's published materials, Weiss Ratings can be reached through the following channels:
Company: Weiss Ratings
Phone: 877-934-7778 (domestic) or +1 561-627-3300 (international)
Email: [email protected]
Disclaimers
Investment Risk Disclaimer: Investing involves risk, including potential loss of principal. Past performance does not guarantee future results. The stock ratings and analysis discussed in this article represent the methodology of Safe Money Report and Weiss Ratings and should not be construed as personalized investment advice. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.
Publisher's Exclusion Notice: According to Weiss Ratings' published terms and conditions, Weiss Ratings, LLC is "strictly a financial research publishing firm (a publisher) and does not provide individual investment advice to its subscribers." The service operates under the publisher's exclusion from investment adviser registration under the Investment Advisers Act. The service provides general financial information and opinions; it does not provide individualized investment advice. Subscribers receive the same information regardless of their personal financial situation.
Results Disclaimer: Stock examples and performance figures cited represent historical data highlighted by Weiss Ratings in their published marketing materials. According to the company's own required risk disclosure, hypothetical performance results have "many inherent limitations" and are "generally prepared with the benefit of hindsight." Featured gains are selected highlights and are not representative of all recommendations or any particular subscriber's experience. Individual investor results vary significantly based on entry timing, position sizing, holding period, and broader market conditions. Losses are possible and have occurred for subscribers.
FTC Affiliate Disclosure: This article contains affiliate links. If you subscribe through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or editorial independence of the information presented.
Pricing Disclaimer: All subscription pricing, promotional offers, bundle values, and refund terms mentioned were based on the company's published materials at the time of publication (February 2026) and are subject to change. Always verify current pricing and terms before subscribing.
Editorial Independence: This analysis is based on publicly available information from Weiss Ratings' marketing materials, published terms and conditions, and general financial industry context. The publisher of this article is not affiliated with Weiss Ratings, LLC beyond the affiliate relationship disclosed above.
SOURCE: Weiss Rating